CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.
  
  LEARNING OBJECTIVES

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe published and emerging research data with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into the treatment algorithm.
  • Incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
  • Appraise clinical trial findings with and discern the clinical applicability of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and identify candidates who may be appropriate for these approaches.
  • Review the rationale for, available and emerging data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Yelena Y Janjigian, MD
  Associate Professor
  Chief of Gastrointestinal Oncology Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AmerisourceBergen, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Geneos Therapeutics, GSK, Imugene, Lilly, Lynx Health LLC, Merck, Merck Serono, Mersana Therapeutics Inc, Michael J Hennessy Associates Inc, Pfizer Inc, Rgenix, Seagen Inc, Silverback Therapeutics, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Nonrelevant Financial Relationship: Imedex, Paradigm Medical Communications, PeerView Institute.
  
  Florian Lordick, MD, PhD
  Full Professor of Medicine at the University of Leipzig
  Director of the University Cancer Center
  Head of Department of Oncology
  Leipzig University
  Leipzig, Germany
  
  Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc; Contracted Research: Bristol Myers Squibb, Gilead Sciences Inc; Data and Safety Monitoring Board/Committee: Bi•oNTech AG; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Incyte Corporation, Lilly, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Imedex, Medscape, MedUpdate, Streamedup.
  
  Zev Wainberg, MD, MSc
  Co-Director, GI Oncology Program
  Director of Early Phase Clinical Research
  Jonsson Comprehensive Cancer Center
  UCLA School of Medicine
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc.
  
  MODERATOR
  
  Samuel J Klempner, MD
  Associate Professor
  Massachusetts General Hospital
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Sanofi; Data and Safety Monitoring Board/Committee: Mersana Therapeutics Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, and Lilly.
  
  Release date: February 2023
  Expiration date: February 2024